Jun. 6 at 9:36 PM
$MXCT We recently reviewed a new MaxCyte stock pitch from Substack.
MaxCyte (NASDAQ: MXCT)
🇺🇸 | $ 228.58 M | Healthcare | Value
MaxCyte, Inc. is a global life sciences company focused on next-generation cell therapies. The current valuation, with a market cap of
$240 million and an enterprise value of
$85 million, suggests significant upside potential. Furthermore, its robust core business benefits from high-margin consumable sales and strategic partnerships, such as with Vertex for the CASGEVY therapy. Additionally, MaxCyte's strong cash position and expanding SPL agreements offer attractive opportunities for future revenue growth.
Link: https://doheenz.substack.com/p/maxcyte-mxct
Our team also analysed 18 other pitches, with the full breakdown available at PitchStack: www.pitchstack-investing.com
